Model Liposomal Delivery System for Drugs and Vaccines

Crossmark: check for updates

Authors

  • Farrhana Z.Firdaus School of Chemistry and Molecular Biosciences,The University of Queensland, St. Lucia, QLD 4072, Australia
  • Zeinab G. Khalil Institute for Molecular Bioscience,The University of Queensland, St. Lucia, QLD 4072, Australia; The University of Queensland Diamantina Institute,The University of Queensland, Brisbane, Queensland, Australia
  • Robert J. Capon Institute for Molecular Bioscience,The University of Queensland, St. Lucia, QLD 4072, Australia
  • Mariusz Skwarczynski School of Chemistry and Molecular Biosciences,The University of Queensland, St. Lucia, QLD 4072, Australia
  • Istvan Toth School of Chemistry and Molecular Biosciences,The University of Queensland, St. Lucia, QLD 4072, Australia; Institute for Molecular Bioscience,The University of Queensland, St. Lucia, QLD 4072, Australia; School of Pharmacy,Woolloongabba,The University of Queensland, QLD 4072, Australia
  • Waleed M. Hussein School of Chemistry and Molecular Biosciences,The University of Queensland, St. Lucia, QLD 4072, Australia

DOI:

https://doi.org/10.17140/VROJ-5-117

Keywords:

Liposomes, Drug delivery, Vaccines delivery, Egg phosphatidylglycerol, Polyethylene glycol

Abstract

Background
Liposomes have been used for drug delivery since their discovery 60-years-ago. The advantages they provide as carriers have been
recognised and exploited to improve the delivery of numerous drugs and eliminate harmful side-effects. Liposomal delivery has
been tested for anticancer drugs, anti-tuberculosis drugs, variety of vaccines, just to list a few.
Methods
We developed a series of liposomal formulations with the addition of cholesterol and polyethylene glycol. The uptake of these
formulations by human epithelial prostate cancer (PC-3) cells and mouse macrophages was examined and analysed by flow
cytometry and confocal microscopy.
Results
Among the liposomes tested, small anionic liposome vesicles (≤200 nm) prepared with egg phosphatidylglycerol as the main lipid
were most effectively taken up by PC-3 cells and macrophages.
Conclusion
We produced a liposome formulation that can be used as a model system for the delivery of drugs and vaccines.

References

Bozzuto, G, Molinari, A Liposomes as nanomedical devices. Int J Nanomedicine. 2015; 10: 975-999. doi: 10.2147/Ijn.S68861

Bangham A. The 1st description of liposomes - a citation classic commentary on Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids by Bangham AD, Standish MM, Watkins JC. Current Contents/Life Sciences. 1989(13): 14. Web site. http:// garfield.library.upenn.edu/classics1989/A1989T670000001.pdf. Accessed July 5, 2020.

Azadi A, Ashrafi H. Cell organelle-shaped liposomes: A novel approach to present the stable intracellular drug delivery systems. Trends in Pharmaceutical Sciences. 2016; 2(2): 85-88.

Torchilin VP. Recent advances with liposomes as pharmaceuti-cal carriers. Nature Reviews Drug Discovery. 2005; 4(2): 145-160. doi: 10.1038/nrd1632 Original Research | Volume 5 | Number 1| Toth I and Hussein WM et al

Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: Classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1): 102. doi: 10.1186/1556- 276X-8-102

Çağdaş M, Sezer AD, Bucak S. Liposomes as potential drug car-rier systems for drug delivery. In: Application of Nanotechnology in Drug Delivery. 2014. doi: 10.5772/58459

Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews. 2013; 65(1): 36-48. doi: 10.1016/j.addr.2012.09.037

Li J, Wang, XL, Zhang, T, Wang C, Huang Z, Luo X, et al. A re-view on phospholipids and their main applications in drug delivery systems. Asian Journal of Pharmaceutical Sciences. 2015; 10(2): 81-98. doi: 10.1016/j.ajps.2014.09.004

Lian, T, Ho, RJ Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90(6): 667-680. doi: 10.1002/ jps.1023

Sofou, S, Sgouros, G Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv. 2008; 5(2): 189-204. doi: 10.1517/17425247.5.2.189

Sawant, RM, Hurley, JP, Salmaso, S, Kale A, Tolcheva E, Levchenko TS, et al. “SMART” drug delivery systems: Double-tar-geted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006; 17(4): 943-949. doi: 10.1021/bc060080h

Pasut, G, Paolino, D, Celia, C, Mero A, Joseph AS, Wolfram J, et al. Polyethylene glycol (PEG)-dendron phospholipids as in-novative constructs for the preparation of super stealth liposomes for anticancer therapy. J Control Release. 2015; 199: 106-113. doi: 10.1016/j.jconrel.2014.12.008

Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research. J Control Release 2012; 161(2): 461-472. doi: 10.1016/j.jconrel.2011.10.037

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003; 2(3): 214-221. doi: 10.1038/nrd1033

Magarkar A, Dhawan V, Kallinteri, P, Viitala T, Elmowafy M, Róg T, et al. Cholesterol level affects surface charge of lipid membranes in saline solution. Sci Rep. 2014; 4: 5005. doi: 10.1038/ srep05005

Yan X, Scherphof GL, Kamps JA. Liposome opsonization. J Liposome Res. 2005; 15(1-2): 109-139. doi: 10.1081/lpr-64971

Henao-Tamayo, M, Shanley, CA, Verma, D, Zilavy A, Sta-pleton MC, Furney SK, et al. The efficacy of the BCG vaccine against newly emerging clinical strains of mycobacterium tuber-culosis. PLoS One. 2015; 10(9): e0136500. doi: 10.1371/journal. pone.0136500

Tameris, MD, Hatherill, M, Landry, BS, Scriba TJ, Snowden MA, Lockhart S, et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871): 1021-1028. doi: 10.1016/S0140-6736(13)60177-4

Piccolo, M, Misso, G, Ferraro, MG, Riccardi H, Capuozzo A, Zarone MR, et al. Exploring cellular uptake, accumulation and mechanism of action of a cationic Ru-based nanosystem in hu-man preclinical models of breast cancer. Sci Rep. 2019; 9(1): 7006. doi: 10.1038/s41598-019-43411-3

Skwarczynski M, Hayashi Y, Kiso Y. Paclitaxel prodrugs: To-ward smarter delivery of anticancer agents. J Med Chem. 2006; 49(25): 7253-7269. doi: 10.1021/jm0602155

Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: A review. JAMA. 2017; 317(24): 2532-2542. doi: 10.1001/ jama.2017.7248

Hema S, Thambiraj S, Shankaran DR. Nanoformulations for targeted drug delivery to prostate cancer: An overview. J Nanosci Nanotechnol. 2018; 18(8): 5171-5191. doi: 10.1166/jnn.2018.15420

Serradell, MC, Rupil, LL, Martino, RA, Prucca CG, Carranza PG, Saura, A et al. Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins. Nat Commun. 2019; 10(1): 361. doi: 10.1038/s41467-018-08265-9

Samad A, Sultana Y, Aqil M. Liposomal drug delivery sys-tems: an update review. Curr Drug Deliv. 2007; 4(4): 297-305. doi: 10.2174/156720107782151269

Kaighn, ME, Narayan, KS, Ohnuki, Y, Lechner JF, Jones LW. Establishment and characterization of a human prostatic carcino-ma cell line (PC-3). Invest Urol. 1979; 17(1): 16-23.

Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016; 7(2): 842-854. doi: 10.1039/c5sc03892h

Skwarczynski, M, Zhao, GZ, Boer, JC, Ozberk V, Azuar A, Cruz JG, et al. Poly(amino acids) as a potent self-adjuvanting de-livery system for peptide-based nanovaccines. Sci Adv. 2020; 6(5): eaax2285. doi: 10.1126/sciadv.aax2285

Thakur A, Mikkelsen H, Jungersen GIntracellular pathogens: Host immunity and microbial persistence strategies. J Immunol Res. 2019; 2019: 1356540. doi: 10.1155/2019/1356540

Al-Attiyah R, El-Shazly A, Mustafa AS. Comparative analysis of spontaneous and mycobacterial antigen-induced secretion of Th1, Th2 and pro-inflammatory cytokines by peripheral blood mononuclear cells of tuberculosis patients. Scand J Immunol. 2012; 75(6): 623-632. doi: 10.1111/j.1365-3083.2012.02692.x

Umeshappa, CS, Xie, Y, Xu, S, Nanjundappa RH, Freywald A, Deng Y, et al. Th cells promote CTL survival and memory via ac-15 Toth I and Hussein WM et al quired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways. PLoS One. 2013; 8(6): e64787. doi: 10.1371/journal.pone.0064787

Olusanya, TOB, Haj Ahmad, RR, Ibegbu, DM, Smith JR, El-kordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules. 2018; 23(4): 907. doi: 10.3390/molecules23040907

Kroon, J, Metselaar, JM, Storm, G, van der Pluijm G. Lipo-somal nanomedicines in the treatment of prostate cancer. Cancer Treat Rev. 2014; 40(4): 578-584. doi: 10.1016/j.ctrv.2013.10.005

Zhang, W, Song, Y, Eldi, P, Guo X, Hayball JD, Garg S, et al. Targeting prostate cancer cells with hybrid elastin-like polypep-tide/liposome nanoparticles. Int J Nanomedicine. 2018; 13: 293-305. doi: 10.2147/IJN.S152485

Khademi, F, Taheri, RA, Momtazi-Borojeni, AA, Farnoosh G, Johnston TP, Sahebkar A. Potential of cationic liposomes as adju-vants/delivery systems for tuberculosis subunit vaccines. Rev Physi-ol Biochem Pharmacol. 2018; 175: 47-69. doi: 10.1007/112_2018_9

Marasini N, Ghaffar KA, Skwarczynski M, Toth I. Liposomes as a vaccine delivery system. In: Micro and Nanotechnology in Vaccine Development. Norwich, NY, USA: William Andrew Inc; 2017: 221- 239.

Ghaffar KA, Marasini N, Giddam AK, Batzloff MR, Good MF, Skwarczynski M, et al. Liposome-based intranasal delivery of lipopeptide vaccine candidates against group A streptococcus. Acta Biomater. 2016; 41: 161-168. doi: 10.1016/j.actbio.2016.04.012

Ghaffar, KA, Giddam, AK, Zaman, M, Skwarczynski M, Toth I. Liposomes as nanovaccine delivery systems. Current Topics in Me-dicinal Chemistry. 2014; 14(9): 1194-1208. doi: 10.2174/1568026614

Zhang M, Desai T, Ferrari M. Proteins and cells on PEG im-mobilized silicon surfaces. Biomaterials. 1998; 19(10): 953-60. doi: 10.1016/s0142-9612(98)00026-x

Wischerhoff, E, Uhlig, K, Lankenau, A, Börner HG, Laschews-ky A, Duschl C, et al. Controlled cell adhesion on PEG-based switchable surfaces. Angew Chem Int Ed Engl. 2008; 47(30): 5666- 568. doi: 10.1002/anie.200801202

Immordino, ML, Dosio, F, Cattel, L Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006; 1(3): 297-315.

Sanchez L, Yi Y, Yu Y. Effect of partial PEGylation on par-ticle uptake by macrophages. Nanoscale. 2017; 9(1): 288-297. doi: 10.1039/c6nr07353k

Takano S, Aramaki Y, Tsuchiya S. Physicochemical proper-ties of liposomes affecting apoptosis induced by cationic lipo-somes in macrophages. Pharm Res. 2003; 20(7): 962-968. doi: 10.1023/a:1024441702398 Original Research | Volume 5 | Number 1|

Epstein-Barash H, Gutman D, Markovsky E, Mishan-Eisen-berg G, Koroukhov N, Szebeni J, et al. Physicochemical parame-ters affecting liposomal bisphosphonates bioactivity for restenosis therapy: Internalization, cell inhibition, activation of cytokines and complement, and mechanism of cell death. J Control Release. 2010; 146(2): 182-195. doi: 10.1016/j.jconrel.2010.03.011

Straubinger, RM, Hong, K, Friend, DS, Papahadjopoulos D. Endocytosis of liposomes and intracellular fate of encapsulated molecules: Encounter with a low pH compartment after inter-nalization in coated vesicles. Cell. 1983; 32(4): 1069-1079. doi: 10.1016/0092-8674(83)90291-x Submit your article to this journal | https://openventio.org/submit-manuscript/ Original Research | Volume 5 | Number 1| Toth I and Hussein WM et al

Muller, WJ, Zen, K, Fisher, AB, Shuman H. Pathways for up-take of fluorescently labeled liposomes by alveolar type II cells in culture. Am J Physiol. 1995; 269(1 Pt 1): L11-L19. doi: 10.1152/ ajplung.1995.269.1.L11

Poelma, DL, Ju, MR, Bakker, SC, Zimmermann LJ, Lachmann BF, van Iwaarden JF. A common pathway for the uptake of surfac-tant lipids by alveolar cells. Am J Respir Cell Mol Biol. 2004; 30(5): 751-758. doi: 10.1165/rcmb.2003-0127OC

Quintero OA, Wright JR. Metabolism of phosphatidylglycerol by alveolar macrophages in vitro. Am J Physiol Lung Cell Mol Physiol. 2000; 279(2): L399-L407. doi: 10.1152/ajplung.2000.279.2.L399

Downloads

Published

2020-08-06

How to Cite

Farrhana Z.Firdaus, Zeinab G. Khalil, Robert J. Capon, Mariusz Skwarczynski, Istvan Toth, & Waleed M. Hussein. (2020). Model Liposomal Delivery System for Drugs and Vaccines. Vaccination Research, 5(1), 10–16. https://doi.org/10.17140/VROJ-5-117

Issue

Vol. 5 No. 1 (2020): Volume 5 Issue 1 2020

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Vaccination Research (VR) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.